Clinical Monograph: Oxandrolone (Anavar)

1. Classification and Chemical Overview

• Active Composition: Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-5-alpha-androstan-3-one), a modified form of DHT featuring a substitution of carbon-2 with an oxygen atom in the steroid ring.

• Therapeutic Class: Anabolic-androgenic steroid (AAS) / Protein synthesis stimulant.

• Regulatory Status: Schedule III controlled substance in the United States and a prescription-only medication globally, strictly regulated due to significant risks of abuse, endocrine disruption, and hepatotoxicity.

2. Mechanism of Action and Pharmacodynamics

• Androgen Receptor Activation: Binds to intracellular androgen receptors in target tissues, stimulating nitrogen retention, enhancing muscle protein synthesis, and decreasing amino acid catabolism.

• Tissue Selectivity: Engineered to exhibit a higher ratio of anabolic to androgenic activity compared to testosterone, minimizing (though not eliminating) virilizing side effects.

• Metabolic Impact: Modulates body composition by promoting lean muscle mass accretion and accelerating recovery from catabolic states, burns, or severe trauma.

3. Approved Clinical Indications and Dosing Scope

• Indications:

  • Adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma.

  • To offset protein catabolism associated with prolonged administration of systemic corticosteroids.

  • Relief of bone pain frequently accompanying osteoporosis.

• Dosing Regimen & Administration:

  • Administered orally. Clinical dosing historically ranges from 2.5 mg to 20 mg per day, divided into 2 to 4 daily doses, depending on the specific medical indication and patient response.

  • Treatment duration is strictly monitored and limited to minimize long-term adverse physiological consequences.

4. Pharmacokinetic Profile

• Absorption & Peak Plasma: Rapidly absorbed from the gastrointestinal tract, achieving peak plasma concentrations within 1 to 1.5 hours post-ingestion.

• Elimination Half-Life: Relatively short elimination half-life of approximately 9 to 10 hours.

• Metabolism & Excretion: Extensively metabolized by the liver (utilizing 17-alpha-alkylation to survive first-pass metabolism, which inherently increases hepatic stress) and excreted primarily through renal elimination.

5. Physiological Effects and Adverse Event Spectrum

Endocrine suppression and hepatic strain represent the most critical physiological hazards associated with use.

Adverse Reaction Profile

• Common ($\ge 1/10$ to $<1/10$): Dyslipidemia (significant decreases in high-density lipoprotein [HDL] cholesterol and increases in low-density lipoprotein [LDL] cholesterol), acne, oily skin, and male pattern hair loss in genetically predisposed individuals.

• Endocrine / Hormonal: Severe suppression of endogenous hypothalamic-pituitary-testicular (HPT) axis, leading to testicular atrophy and oligospermia or azoospermia in males; virilization in females (deepening of the voice, clitoral enlargement, facial hair growth, and menstrual irregularities).

• Hepatic / Rare (<1/1,000): Hepatotoxicity, ranging from elevations in serum transaminases to peliosis hepatis, hepatic adenomas, and cholestatic jaundice. Cardiovascular risks include elevated blood pressure, left ventricular hypertrophy, and heightened risk of thrombotic events.

6. Contraindications, Drug Interactions, and Clinical Precautions

Contraindications

• Known or suspected carcinoma of the prostate or breast in male patients.

• Pregnancy and breastfeeding (due to severe risks of fetal masculinization and teratogenicity).

• Nephrosis or severe renal impairment.

• Severe hepatic dysfunction or active liver disease.

• Hypercalcemia.

Key Interacting Factors & Warnings

• Anticoagulants: Anabolic steroids can significantly increase sensitivity to oral anticoagulants (e.g., warfarin), heightening the risk of major bleeding events; dosage adjustments and close monitoring of International Normalized Ratio (INR) are required.

• Insulin and Oral Hypoglycemics: Can lower blood glucose levels, necessitating careful monitoring and potential adjustment of antidiabetic medications.